603718 Shanghai Hile Bio-Technology
- 6.90
- +0.27+4.07%
Shanghai Hile Bio-Technology News
Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Price Is Out Of Tune With Revenues
When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.1x, you may consider Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) as a s
Some May Be Optimistic About Shanghai Hile Bio-Technology's (SHSE:603718) Earnings
The market for Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) shares didn't move much after it posted weak earnings recently. Our analysis suggests that while the profits are soft, the founda
Investors in Shanghai Hile Bio-Technology (SHSE:603718) From Three Years Ago Are Still Down 52%, Even After 7.8% Gain This Past Week
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) shareholders know that all too well, since the shar
Hailey Biotech (603718.SH): Net loss of 3.719 million yuan in the first quarter
Gelonghui, April 29丨Hailey Biotech (603718.SH) released its first quarter report. Operating revenue was 70.3 million yuan, down 1.31% year on year, net loss of 3.79 million yuan, net loss of 5.29 million yuan after non-net loss, and basic earnings per share -0.01 yuan.
Individual Investors in Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 13% Last Week
Key Insights Significant control over Shanghai Hile Bio-Technology by individual investors implies that the general public has more power to influence management and governance-related decisions A t
More Unpleasant Surprises Could Be In Store For Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Shares After Tumbling 31%
The Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) share price has fared very poorly over the last month, falling by a substantial 31%. Instead of being rewarded, shareholders who have alread
Shanghai Hile Bio-Technology (SHSE:603718) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Earnings Growth of 2.8% Over 5 Years Hasn't Been Enough to Translate Into Positive Returns for Shanghai Hile Bio-Technology (SHSE:603718) Shareholders
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But even the best stock picker will only win with some selections. At
Hailey Biotech (603718.SH) received a warning letter from the Shanghai Securities Regulatory Bureau
Hailey Biotech (603718.SH) issued an announcement. The company recently received a decision on administrative supervision measures from the Shanghai Securities Regulatory Bureau...
Hailey Biotech (603718.SH): Plans to use no more than 300 million yuan of idle own funds to entrust financial management
Gelonghui (603718.SH) announced that on December 12, 2023, Hailey Biotech () announced that on December 12, 2023, the company held the 20th meeting of the fourth board of directors and the 16th meeting of the fourth board of supervisors to deliberate and pass the “bill on the company's use of idle own funds to entrust financial management”, and agreed to use no more than 300,000 yuan of idle own funds to purchase investment and wealth management products issued by financial institutions such as commercial banks, securities companies, fund companies, trust companies, asset management companies, etc., since the fourth board of directors Consideration and adoption at the 20th meeting
[BT Financial Report Instantaneous Analysis] Hailey Biotech's 2023 Quarterly Report Perspective: Seek New Opportunities Amidst Challenges, Significant Growth in Net Profit
Hailey Biotech (stock code: 603718) is a publicly traded company involved in both the veterinary biological products and in vitro diagnostic (IVD) industries. Faced with challenges such as industry reshuffling, environmental protection policies, anti-resistance measures, and African swine fever, Hailey Biotech has responded positively to maintain market competitiveness by increasing investment in R&D to improve product quality and technical service levels. At the same time, the company is also seizing the rapid development opportunities in the field of in vitro diagnostics, especially on tracks such as molecular diagnosis and POCT, and strives to enhance independent R&D and production capacity to adapt to the trend of domestic production substitution. In terms of assets and liabilities, according to the 2023 three-quarter report
If EPS Growth Is Important To You, Shanghai Hile Bio-Technology (SHSE:603718) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investment
Hailey Biotech (603718.SH) released the first three quarter results, net profit of 74.6985 million yuan, up 86.47% year on year
Hailey Biotech (603718.SH) released its report for the first three quarters of 2023, with revenue of 195 million yuan...
Shanghai Hile Bio-Technology (SHSE:603718) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' It's only natural to co
Hailey Biotech (603718.SH): Grants 17.9 million stock options and 13.9 million restricted shares to incentive recipients
GLONGHUI September 5 | Hailey Biotech (603718.SH) announced that the company agreed to grant 13.9 million restricted shares to 78 incentive recipients and 17.9 million stock options to 98 incentive recipients.
Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Shanghai Hile Bio-Technology (SHSE:603718) has had a great run on the share market with its stock up by a significant 6.8% over the last week. We wonder if and what role the company's financials pla
Hailey Biotech (603718.SH) released first-half results, net profit of 446.791 million yuan, an increase of 47.59% over the previous year
Hailey Biotech (603718.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Hailey Biotech (603718.SH): Plans to introduce 32 million restricted stock and stock options incentive plan
Glonghui, August 18: Hailey Biotech (603718.SH) announced the 2023 restricted stock and stock options incentive plan. The total number of shares to be granted to incentive recipients was 32 million shares, accounting for about 4.97% of the company's total share capital of 644 million shares at the time the draft incentive plan was announced. There were no reserved rights. The grant price was 4.78 yuan/share, and the total number of incentive recipients was 99.
Hailey Biotech (603718.SH): General manager Chen Xiao resigns and hires Han Benyi as general manager
According to the Zhitong Finance App, Hailey Biotech (603718.SH) announced that the company's board of directors recently received a report on the resignation of Chen Xiao, the company's general manager. Due to personal reasons, Chen Xiao requested to resign as the company's general manager. Following the nomination of the company's chairman and review by the nomination committee of the company's board of directors, the board of directors of the company agreed to appoint Han Benyi as the company's general manager and Chen Xiao and Liu Yanlin as the company's deputy general managers. The term of office starts from the date of review and approval by the board of directors until the end of the fourth board of directors.
Hailey Biotech (603718.SH) distributes 0.0567 yuan per share in 2022. The share registration date is July 12
According to the Zhitong Finance App, Hailey Biotech (603718.SH) announced that the company will implement the 2022 annual equity distribution, with a cash dividend of 0.0567 yuan (tax included) per share. The share registration date is July 12.
Analysis
Price Target
No Data
